The European Commission has granted conditional marketing authorization (CMA) for CSL's HEMGENIX, the first and only one-time gene therapy for the treatment of severe and moderately severe hemophilia B in adults without a history of Factor IX inhibitors.
In the ongoing clinical trial, HEMGENIXÂ r